Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Cited In for PubMed (Select 12968127)

1.

Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.

Smucny J, Stevens KE, Olincy A, Tregellas JR.

Transl Psychiatry. 2015 Jun 23;5:e587. doi: 10.1038/tp.2015.77. Review.

2.

Small effects of smoking on visual spatiotemporal processing.

Kunchulia M, Pilz KS, Herzog MH.

Sci Rep. 2014 Dec 4;4:7316. doi: 10.1038/srep07316.

3.

Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date.

Potter AS, Schaubhut G, Shipman M.

CNS Drugs. 2014 Dec;28(12):1103-13. doi: 10.1007/s40263-014-0208-9. Review.

PMID:
25349138
4.

The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases.

Lam J, Coleman N, Garing AL, Wulff H.

Expert Opin Ther Targets. 2013 Oct;17(10):1203-20. doi: 10.1517/14728222.2013.823161. Epub 2013 Jul 25. Review.

5.

An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia.

Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE.

J Dual Diagn. 2013;9(1):87-93.

6.

Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Jones CK, Byun N, Bubser M.

Neuropsychopharmacology. 2012 Jan;37(1):16-42. doi: 10.1038/npp.2011.199. Epub 2011 Sep 28. Review.

7.

Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A.

Arch Gen Psychiatry. 2011 Dec;68(12):1195-206. doi: 10.1001/archgenpsychiatry.2011.83. Epub 2011 Aug 1.

8.

Functional brain imaging of nicotinic effects on higher cognitive processes.

Newhouse PA, Potter AS, Dumas JA, Thiel CM.

Biochem Pharmacol. 2011 Oct 15;82(8):943-51. doi: 10.1016/j.bcp.2011.06.008. Epub 2011 Jun 13. Review.

9.

TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.

Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA, Stachowiak EK, Stachowiak MK, Papke RL, Lippiello PM, Bencherif M.

Biochem Pharmacol. 2009 Oct 1;78(7):803-12. doi: 10.1016/j.bcp.2009.05.030. Epub 2009 May 29.

10.

Smoking, Genetics and Schizophrenia: Evidence for Self Medication.

Leonard S, Mexal S, Freedman R.

J Dual Diagn. 2007 Nov 1;3(3-4):43-59.

11.

Pharmacological treatment effects on eye movement control.

Reilly JL, Lencer R, Bishop JR, Keedy S, Sweeney JA.

Brain Cogn. 2008 Dec;68(3):415-35. doi: 10.1016/j.bandc.2008.08.026. Review.

12.

Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia.

Dale Horst W, Klein MW, Williams D, Werder SF.

Neuropsychiatr Dis Treat. 2005 Dec;1(4):349-55.

13.

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.

Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE.

Schizophr Res. 2008 Jul;102(1-3):88-95. doi: 10.1016/j.schres.2007.12.491. Epub 2008 Mar 5.

14.

Smoking cessation in patients with psychiatric disorders.

Gelenberg AJ, de Leon J, Evins AE, Parks JJ, Rigotti NA.

Prim Care Companion J Clin Psychiatry. 2008;10(1):52-8. No abstract available.

15.

Neurophysiological biomarkers for drug development in schizophrenia.

Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajós M.

Nat Rev Drug Discov. 2008 Jan;7(1):68-83. Review.

16.

Nicotine consumption and schizotypy in first-degree relatives of individuals with schizophrenia and non-psychiatric controls.

Esterberg ML, Jones EM, Compton MT, Walker EF.

Schizophr Res. 2007 Dec;97(1-3):6-13. Epub 2007 Sep 25.

17.

Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Levin ED, Rezvani AH.

Biochem Pharmacol. 2007 Oct 15;74(8):1182-91. Epub 2007 Jul 20. Review.

18.

Visual scan paths in first-episode schizophrenia and cannabis-induced psychosis.

Benson PJ, Leonards U, Lothian RM, St Clair DM, Merlo MC.

J Psychiatry Neurosci. 2007 Jul;32(4):267-74.

19.

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA.

Schizophr Bull. 2007 Sep;33(5):1120-30. Epub 2007 Jul 19. Review.

20.

Cholinergic circuits and signaling in the pathophysiology of schizophrenia.

Berman JA, Talmage DA, Role LW.

Int Rev Neurobiol. 2007;78:193-223. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk